Lirilumab
Lirilumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Lirilumab Usage And Synthesis
Uses
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].
in vivo
Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2].
| Animal Model: | Rag1KO-Tg KIR mice injected with tumor cells[2] |
| Dosage: | 15 mg/kg |
| Administration: | intravenous injection; 15 mg/kg; once |
| Result: | Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
References
[1] Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. DOI:10.1158/1078-0432.CCR-21-2635
[2] Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. DOI:10.1182/blood-2013-08-519199
LirilumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com